GlassScriptPhysician profile
Thomas C Dunne
NPI 1518939115
$1,410.86
in general payments reported to CMS, 2019-2025
17 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $180 · 2021: $23.77 · 2022: $37.59 · 2023: $68.23 · 2024: $119 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653 · Consulting Fee: $358 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.39 |
| Consulting Fee | $358.35 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.37 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $358.35 | 2025 | |
| Supernus Pharmaceuticals, INC. | $157.24 | 2019-2020 | |
| Genzyme Corporation | $112.44 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $63.08 | 2023-2025 | |
| Neurelis, INC. | $43.76 | 2024-2025 | Valtoco |
| E.R. Squibb & Sons, L.L.C. | $41.19 | 2020 | |
| Upsher-Smith Laboratories LLC | $33.41 | 2025 | |
| Pfizer INC. | $27.49 | 2024 | |
| Dynasplint Systems INC. | $25.33 | 2025 | Dynasplint |
| Celgene Corporation | $24.90 | 2023 | Zeposia |
| Lundbeck LLC | $24.43 | 2023 | Vyepti |
| Sanofi-Aventis U.S. LLC | $23.77 | 2021 | |
| Abbott Laboratories | $23.13 | 2020 | |
| Kyowa Kirin, INC. | $21.13 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $19.29 | 2025 | |
| Ucb, INC. | $18.55 | 2024 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dunne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.